CLINICAL EXPERIENCE WITH IMMUNOGLOBULIN SIGARDIS AS REPLACEMENT THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY


Cite item

Abstract

Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory efficacy of the drug. 

About the authors

V. G. Drobyshevskaya

St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology;
First St. Petersburg State I. Pavlov Medical University

Author for correspondence.
Email: v.g.drobyshevskaia@yandex.ru

аllergist-immunologist, Medical Center;

high school teacher, Department of Immunology,

St. Petersburg

Russian Federation

O. A. Krivtsun

First St. Petersburg State I. Pavlov Medical University

Email: fake@neicon.ru

student,

St. Petersburg

Russian Federation

References

  1. Латышева Е. А. «Первичные иммунодефициты у взрослых. Особенности диагностики и лечения.», Москва, 2018 г.
  2. Федеральные клинические рекомендации по диагностике и лечению больных первичными иммунодефицитами с нарушением гуморального звена. РААКИ, Москва 2014 год.

Copyright (c) 2019 Drobyshevskaya V.G., Krivtsun O.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies